Skip to main content
Fig. 1 | BMC Endocrine Disorders

Fig. 1

From: The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile

Fig. 1

Accumulated food intake for the initial 7 days (a) and for the entire duration of the study (b). Body weights at study end (c). Calculated food efficiency (d). N = 8–10 rats per group. Statistical analysis between groups were performed as a one-way ANOVA followed by Tukey’s post-hoc test with the following annotations: *P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle, #P < 0.05, ##P < 0.01 vs. liraglutide (200 μg/kg), §P < 0.05, §§P < 0.01 vs. liraglutide (400 μg/kg), ¤ P < 0.05, ¤¤ P < 0.01, ¤¤¤ P < 0.001 vs. KBP-089 (0.625 μg/kg), † P < 0.05, †† P < 0.01, ††† P < 0.001 vs. KBP-089 (1.25 μg/kg) and ‡‡P < 0.01 vs. KBP-089 (2.5 μg/kg). All data are means ± SEM

Back to article page